EPFL Investor Day 2024

10 Dec 2024 | Lausanne, Switzerland

Christoph Merten

EPFL Professor, Co-founder of TheraMe!

TheraMe!

Lausanne, Switzerland

26 profile visitsSpeaker

About me

Prof. Christoph A. Merten is a professor for biomedical microfluidics at EPFL and holds an adjunct position at the Ludwig Institute for Cancer Research. In parallel, he has commercialized microfluidic technology and collaborated with big pharma. Christoph is a co-founder of TheraMe! and sole scientific founder of Velabs Therapeutics, now operating as Veraxa Biotech.

My organisation

Why going for a standardized cancer therapy if there are no standardized cancers? TheraMe! finds the best cancer treatment option, for each patient, at any stage of the disease.

Social media

Speaker sessions (1)

Tuesday, 10 December 2024

10:15 - 11:20

Pitch Sessions Healthtech

Format:In-personLocation:Pitch Area 1Track:Pitch Session

Experience the forefront of healthtech innovation at EPFL Investor Day!